Regeneron: Can Dupixent's Growth Actually Replace What Eylea Is Losing to Biosimilars?

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Regeneron reports before the market opens, meaning Day 0 represents the first full trading session where investors react to results, while Day +1 captures follow-through momentum.

Historical price action around earnings shows significant volatility, with an average absolute Day 0 move of 6.04% and Day +1 follow-through averaging 2.42%. The most dramatic reaction came in October 2025, when the stock surged 11.82% on earnings day following a strong beat, though it gave back some gains the next session. Conversely, the stock has also experienced sharp selloffs, including a 9.17% decline in October 2024 and a 6.87% drop in April 2025, demonstrating that misses or disappointing guidance can trigger substantial downside.

The pattern suggests that initial reactions tend to be more pronounced than next-day follow-through, with Day 0 ranges averaging 7.10% compared to Day +1 ranges of 3.95%. Recent quarters have shown more moderate moves, with the July 2026 report producing a 6.17% gain on Day 0 and 3.29% on Day +1, while April 2026 saw a 6.21% decline initially followed by a 3.02% recovery. This historical volatility indicates that investors should prepare for meaningful price swings in either direction, with the magnitude likely dependent on whether the company can deliver another substantial beat and provide confidence on the Eylea-to-Dupixent transition story.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 3.62% for this earnings release, which is notably more conservative than the stock's historical average absolute Day 0 move of 6.04%. This suggests options traders may be underpricing potential volatility, or alternatively, that recent quarters' more moderate swings are tempering expectations compared to the dramatic moves seen in late 2024 and early 2025.

Part 3: What Analysts Are Saying

Analyst sentiment on Regeneron remains decidedly bullish heading into the third-quarter report. The current consensus shows 19 Strong Buy ratings and 2 Moderate Buy ratings against 9 Hold ratings, with zero Sell or Strong Sell recommendations among the 30 analysts covering the stock. This translates to an average recommendation of 4.33 on the 5-point scale, reflecting strong conviction in the company's prospects.

The consensus price target stands at $866.97, implying approximately 5.9% upside from the current price of $818.77. Price targets range from a low of $740.00 to a high of $1,030.00, with the wide spread reflecting differing views on how successfully Regeneron can navigate the Eylea-to-Dupixent transition and monetize its pipeline. The most recent rating action came from Canaccord Genuity on October 28, 2026, which maintained its Buy rating while raising its price target from $875 to $922, signaling increased confidence just days before the earnings release.

Sentiment has improved over the past month, with the number of Strong Buy ratings increasing from 18 to 19. This positive shift suggests analysts are growing more confident in the company's ability to deliver on its growth story, likely driven by Dupixent's continued momentum, the expanded Sanofi collaboration worth up to $8 billion, and progress on pipeline programs like cemdisiran. The strengthening consensus heading into earnings indicates the Street expects another solid quarter, though the relatively modest implied upside to the average price target suggests much of the positive outlook may already be reflected in the current valuation.

Part 4: Technical Picture

Regeneron's technical setup heading into earnings shows strong momentum across multiple timeframes. The Barchart Technical Opinion currently registers 88% Buy, a significant strengthening from 72% Buy one week ago and 40% Buy one month ago, indicating accelerating bullish momentum as the earnings date approaches.

Timeframe Analysis:

• Short-term (50% Buy): Moderate buy signal suggests near-term momentum is positive but not overwhelming, indicating some consolidation or profit-taking ahead of the event
• Medium-term (100% Buy): Strong buy signal across the intermediate timeframe reflects solid upward momentum over recent weeks
• Long-term (100% Buy): Maximum bullish reading indicates the longer-term trend remains firmly positive, providing a supportive backdrop for the earnings release

Trend Characteristics: The trend is characterized as Good strength and Strengthening direction, suggesting momentum is building rather than fading as the company approaches its earnings report.

The stock is trading above all key moving averages, with the current price of $818.77 positioned above the 5-day ($812.17), 10-day ($806.59), 20-day ($779.26), 50-day ($791.28), 100-day ($739.35), and 200-day ($736.67) moving averages. This alignment indicates a healthy uptrend with no immediate overhead resistance from technical levels.

The technical picture is decidedly supportive heading into earnings, with the stock in a clear uptrend and momentum indicators strengthening rather than showing signs of exhaustion. The fact that the stock has pulled away from all major moving averages provides a cushion for potential disappointment, though it also means there's less nearby support if results or guidance fall short. The strengthening Barchart Opinion signal from 40% to 88% Buy over the past month suggests technical traders are positioning for continued upside, which could amplify gains if the company delivers another beat but also raises the risk of a sharper reversal if expectations aren't met. Overall, the technical setup favors the bulls, but the strong recent run-up means the bar for a positive reaction may be elevated.